Morgan Stanley’s Apexigen, Inc. Common Stock APGN Stock Holding History

Morgan Stanley’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-49	Closed	–	–	8011
2022 Q3	$0	Buy	+49	New	+$399	﹤0.01%	8006

Other funds holding APGN

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley's APGN Position: Q4 2022 in Review

Morgan Stanley sold out of Apexigen, Inc. Common Stock (APGN) in Q4 2022, closing a stake of 49 shares.

Morgan Stanley first reported a position in APGN in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 15 funds tracked by Wall St. Rank hold APGN as of Q4 2022.

Morgan Stanley reported no remaining Apexigen, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Morgan Stanley sold 49 Apexigen, Inc. Common Stock shares in Q4 2022.
Morgan Stanley first reported a position in Apexigen, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
Morgan Stanley's Apexigen, Inc. Common Stock position peaked at $0 in Q3 2022.
15 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q4 2022.

Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.